A large pharmaceutical firm recently introduced a newer version of its . The new product is identical to the basic version except that it includes an ingredient to alleviate nausea, the most common side effect of the basic remedy. However, during the first six months that both products were on the market, the company sold more than six times as much of the basic remedy as it did of the newer version. The pharmaceutical company therefore decided that avoiding side effects was not the primary consideration of customers who bought its headache remedies.
Which of the following, if true, would most call into question the pharmaceutical company's conclusion?
A. The pharmaceutical company sells its headache remedies to hospitals and clinics as well as to retail distributors.
B. Customers who buy headache remedies made by this firm also buy other pharmaceutical products that cause minor side effects.
C. The new headache remedy and the basic headache remedy both cause side effects other than nausea in less than 1 percent of all users.
D. Because of the risk of unknown or unexpected side effects, many customers avoid new pharmaceutical products until they have been proven to be safe over time.
E. No significant difference in price exists between the new headache remedy and the basic headache remedy.